This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003 Feb;51(2):219-23.

doi: 10.1093/jac/dkg109.

The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1

Damian J McColl¹, Michael D Miller

Affiliations

PMID: 12562684
DOI: 10.1093/jac/dkg109

Review

The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1

Damian J McColl et al. J Antimicrob Chemother. 2003 Feb.

. 2003 Feb;51(2):219-23.

doi: 10.1093/jac/dkg109.

Authors

Damian J McColl¹, Michael D Miller

Affiliation

¹ Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA.

PMID: 12562684
DOI: 10.1093/jac/dkg109

No abstract available

PubMed Disclaimer

Similar articles

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB, Stone EA, Piacenti FJ. Fung HB, et al. Clin Ther. 2002 Oct;24(10):1515-48. doi: 10.1016/s0149-2918(02)80058-3. Clin Ther. 2002. PMID: 12462284 Review.
Tenofovir disoproxil fumarate.
Kumar A. Kumar A. Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00008. Drugs. 2003. PMID: 12887267 No abstract available.
Tenofovir disoproxil fumarate.
Antoniou T. Antoniou T. Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00007. Drugs. 2003. PMID: 12887266 No abstract available.
Tenofovir disoproxil fumarate.
Chapman T, McGavin J, Noble S. Chapman T, et al. Drugs. 2003;63(15):1597-608. doi: 10.2165/00003495-200363150-00006. Drugs. 2003. PMID: 12887265 Review.
Tenofovir disoproxil fumarate (Viread).
Porche DJ. Porche DJ. J Assoc Nurses AIDS Care. 2002 May-Jun;13(3):100-2. doi: 10.1177/10529002013003007. J Assoc Nurses AIDS Care. 2002. PMID: 12064015

See all similar articles

Cited by

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study).
Iwuji C, Waters L, Milinkovic A, Orkin C, Fox J, Post F, Perry N, Bruce C, Dailey N, To Y, Bremner S, Churchill D, Geretti AM. Iwuji C, et al. Virol J. 2025 Feb 10;22(1):33. doi: 10.1186/s12985-025-02648-3. Virol J. 2025. PMID: 39930490 Free PMC article. Clinical Trial.
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD. White KL, et al. Antimicrob Agents Chemother. 2004 Mar;48(3):992-1003. doi: 10.1128/AAC.48.3.992-1003.2004. Antimicrob Agents Chemother. 2004. PMID: 14982794 Free PMC article.
Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. Vardhanabhuti S, et al. Open Forum Infect Dis. 2016 Aug 24;3(3):ofw154. doi: 10.1093/ofid/ofw154. eCollection 2016 Sep. Open Forum Infect Dis. 2016. PMID: 27704010 Free PMC article.
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.
Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, Sarafianos SG. Hachiya A, et al. PLoS One. 2011 Jan 13;6(1):e16242. doi: 10.1371/journal.pone.0016242. PLoS One. 2011. PMID: 21249155 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems